help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 12, No. 9, 1143-1150, September 2007; doi:10.1634/theoncologist.12-9-1143
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jordan, K.
Right arrow Articles by Schmoll, H.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jordan, K.
Right arrow Articles by Schmoll, H.-J.

Symptom Management and Supportive Care

Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future Recommendations

Karin Jordan, Christoph Sippel, Hans-Joachim Schmoll

Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle/Wittenberg, Halle/Saale, Germany

Key Words. Antiemetic therapy • ASCO antiemetic guidelines • MASCC antiemetic guidelines • NCCN practice antiemesis guidelines • 5-HT3 serotonin-receptor antagonists • Neurokinin1-receptor antagonist

Correspondence: Karin Jordan, M.D., Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle/Wittenberg, Ernst-Grube-Str. 40, 06120 Halle/Saale, Germany. Telephone: 49-345-557-2924; Fax: 49-345-557-2950; e-mail: Karin.jordan{at}medizin.uni-halle.de

Disclosure: No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

Clinicians should be aware that chemotherapy-induced nausea and vomiting (CINV) is still one of the most feared side effects of chemotherapy. With the correct use of antiemetics, CINV can be prevented in almost 70% to up to 80% of patients. Treatment guidelines are useful tools that enable physicians to integrate the latest clinical research into their practices. The large volume of rapidly evolving clinical data has been summarized and incorporated into treatment recommendations by well-known and reliable institutions, including the Multinational Association of Supportive Care in Cancer, the American Society of Clinical Oncology, and the National Comprehensive Cancer Network. Despite the availability of such guidelines, however, there is evidence that adherence to and implementation of treatment recommendations are less than optimal. This review focuses, in particular, on the conformity and differences of these three guidelines. Furthermore, open questions and trends in the field of antiemesis are discussed as well.




This article has been cited by other articles:


Home page
 Anticancer ResHome page
K. TAGUCHI, H. IIHARA, M. ISHIHARA, Y. KOMORI, K. TANIZAWA, K. MATSUURA, and Y. ITOH
Comparison of Antiemetic Efficacy between Single and Repeated Treatments with a 5-HT3 Receptor Antagonist in Breast Cancer Patients with High-risk Emetogenic Chemotherapy
Anticancer Res, May 1, 2009; 29(5): 1721 - 1725.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2007 by AlphaMed Press.